cv - Georgetown University

R EBECCA B.

R IGGINS , P H .D.

Georgetown University Medical Center

E412 New Research Building

3970 Reservoir Road, NW

Washington, DC 20057

(202) 687-1260 (office)

(202) 687-5503 (lab)

(202) 687-7505 (fax)

Riggins Lab Website

EDUCATION

Hood College, Frederick, MD B.A., Biochemistry, cum laude

University of Virginia, Charlottesville, VA Ph.D., Microbiology

8/1994 – 5/1998

8/1998 – 5/2003

Georgetown University, Washington, DC Postdoctoral Fellowship, Oncology 6/2003 – 9/2006

PROFESSIONAL EXPERIENCE

Research Track Assistant Professor, Department of Oncology

Breast Cancer Program

9/2006 – 12/2010

Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC

Assistant Professor , Department of Oncology 1/2011* – present

Breast Cancer Program

Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC

*Time in service towards tenure eligibility began 7/1/2011

HONORS AND AWARDS

National Science Foundation Graduate Research Fellowship Program,

Honorable Mention

NIH-funded Molecular Biology of Cancer Training Grant, T32-CA09109

Pre-doctoral Trainee, University of Virginia

1998

1998 – 2003

Selected to attend the Edward A. Smuckler Pathobiology of Cancer Workshop, 2001

Keystone, CO (sponsored by the American Association for Cancer Research)

NIH-funded Tumor Biology Training Grant, T32-CA09686

Postdoctoral Trainee, Lombardi Comprehensive Cancer Center

2003 – 2004

Selected to attend the Susan G. Komen Breast Cancer Career Mentoring

Program for Postdoctoral Fellows

Fourth Annual Future of Breast Cancer Congress: Individualizing Breast

2005

Cancer Treatment, Southampton, Bermuda

Postdoctoral Division Finalist, 20 th

Annual Student Research Days Competition, 2006

Office of Biomedical Graduate Education, Georgetown University

Invited to attend the 2007 Annual Meeting of the Cancer Biology Training

Consortium (CABTRAC), Vergennes VT

2007

Invited Delegate, 2009 Controversies in Breast Cancer Meeting,

Edinburgh, U.K.

Appointed to the Executive Advisory Board for the U.K. Breast Cancer

2009

2012

Campaign Gap Analysis, 2012-2013

Finalist, Gerald M. Mara Faculty Mentorship Award, Georgetown University 2014

John Eisenberg Career Development Award, Georgetown Women in Medicine 2014

Selected to attend the Association of American Medical Colleges 2014

(AAMC) Early Career Women Faculty Professional Development

Seminar, Englewood, CO

Tumor Biology Training Program Excellence in Teaching Award,

Georgetown University

PROFESSIONAL SOCIETIES

2014

Member, American Association for Cancer Research (AACR) and Women in Cancer Research (WICR)

Member, Group on Women in Medicine and Science (GWIMS),

American Association of Medical Colleges (AAMC)

PUBLIC SERVICE

2001 – present

2014 – present

Ad Hoc Manuscript Reviewer: Cancer Research, Clinical Cancer Research, 2005 – present

BMC Cancer, Nutrition & Cancer, Expert Reviews in Molecular Medicine,

Breast Cancer Research and Treatment, Anti-Cancer Drug,

Breast Cancer Research, Genome Medicine, Endocrine-Related Cancer,

Molecular and Cellular Endocrinology, Molecular Cancer Therapeutics,

Oncogene, American Journal of Pathology, PloS ONE, Nanomedicine, Cell

Proliferation

2006 - 2009 Ad Hoc Grant Reviewer, Dutch Cancer Society (KWF Kankerbestrijding),

Breast Cancer Campaign (U.K. and Republic of Ireland),

Health Research Board Ireland, Florida Department of Health

Ad Hoc Study Section Member, Department of Defense Breast Cancer

Research Program (BCRP) TRN-CBY, IPD-CBY, and IIT panels

2009 – 2010

Ad Hoc Study Section Member, National Institute of Environmental

Health Sciences (NIEHS) Special Emphasis Panel ZES1 LWJ-J-(DI)1

Riggins CV 2

2011

Editorial Board member, Frontiers in Pharmacology of Anti-Cancer Drugs 2011- present

Ad Hoc Study Section Member, National Cancer Institute (NCI)

Special Emphasis Panel for review of Provocative Questions

RFA CA-11-011 and -012

Ad Hoc Grant Reviewer, Research Grant Council of Hong Kong

Editorial Board member, Integrative Cancer Science and Therapeutics

2012

2013

2014 – present

Member, Triple Negative and Correlative Science Working Groups of the Translational Breast Cancer Research Consortium http://recovery.nih.gov/Stories/ViewStory.aspx?id=454

AACR 102 nd Annual Meeting Public Policy Press Conference on

Federal funding for cancer research http://traffic.libsyn.com/aacr/AACR_Public_Policy_Press_Conference.mp3

2014 – present

Outreach/Media Relations

AACR 100 th

Annual Meeting Promotional Video

“History of the American Association for Cancer Research”

2009 http://www.youtube.com/watch?v=whxZb0OS_bE&list=UUxr_bGdhkdyyFo5V3qDBwGg

Office of the Director, National Institutes of Health (NIH) 2009

American Recovery and Reinvestment Act (ARRA) Research Funding

Promotional Video

2011

Bloomberg News interview on effects of sequestration on Federal research funding

2013 http://www.bloomberg.com/news/2013-04-04/tumors-on-ice-as-budget-impasse-freezes-medicalresearch.html

PBS News Hour interview on effects of sequestration on Federal research 2013 funding http://www.pbs.org/newshour/rundown/sequester-cuts-to-science-puts-medical-resarch-on-hold/

Kojo Nnamdi Show panel discussion on young scientists and the research funding crunch

2015 http://thekojonnamdishow.org/shows/2015-01-29/young_scientists_and_the_research_funding_crunch

INVITED LECTURES

“Finding a Home for an Orphan Nuclear Receptor”

Departments of Biology and Chemistry Joint Seminar

Hood College, Frederick, MD USA

“Introduction to Molecular Biology for Engineers”

Department of Electrical and Computer Engineering,

2/21/2013

9/18/2013

Riggins CV 3

Virginia Tech, Arlington, VA USA

Invited Speaker for symposium on biomedical research careers

Elizabeth J. Somers Women’s Leadership Program

George Washington University, Washington, DC USA

UNIVERSITY SERVICE

4/9/2015

Department

Member, LCCC Genomics and Epigenomics Shared Resource

Advisory Committee, Department of Oncology

2009 - 2012

Member, LCCC Faculty Liaison Committee, Department of Oncology 2012 – 2015

Member, MedStar Georgetown Cancer Network: Breast Cancer Disease Group 2013 – 2015

Chair, Breast Cancer Program Steering Committee, Department of Oncology 2012 – present

Member, LCCC Clinical Research Committee, Department of Oncology 2014 – present

2014 – present Member, Tumor Biology Training Program Oversight Committee,

Department of Oncology



PhD Admissions Subcommittee (2014-present)



Curriculum Review Subcommittee (2015)

Member, Biospecimen Use Committee, Department of Oncology 2015 - present

School

Member, Georgetown Women in Medicine (GWIM) John Eisenberg

Career Development Award Selection Subcommittee

University

Full Member, Georgetown University Animal Care and Use Committee

(GUACUC)

Alternate Voting Member, GUACUC

TEACHING ACTIVITIES

2015

2011 – 2014

2014 – present

Graduate Biomedical Education Courses

Spring 2005, 2009, 2010 BIOL 500: Dietary Cancer Prevention/Nutrition

UDC/Georgetown Master’s Program in Cancer Biology, Prevention, and

Control

Role: Lecturer

Lecture Titles: “Nutrition and Cancer Risk: Vitamins A and D,” and

“Basics of Endocrinology”

Two contact hours

Number of Students: 4-6

Riggins CV 4

Fall 2010

Spring 2011

Fall 2011

Fall 2009

Spring 2010

Overall Evaluation Score: N/A (not administered by course director)

TBIO 508: Tumor Biology I, Cellular and Molecular Aspects of the

Transformed Cell

Tumor Biology PhD and Master’s program


Role: Lecturer

Lecture Title: “Role of apoptosis in cancer development and therapeutic response”

One contact hour

Number of Students: 26

Overall Evaluation Score: 4.72 out of 5

NSCI 532: Skills and Ethics to Survive and Thrive in Science

Interdisciplinary Program in Neuroscience


Role: advisor

No lecture: advisor for grant writing skills for graduate students

Two contact hours

Number of Students: 3 (assigned to me)



Transformed Cell


Role: Lecturer

Lecture Titles: “Growth Factors and their Receptors,” and “Hormones and Cancer”

Two contact hours



CBIO 539: Molecular and Cellular Biology


Role: Lecturer

Lecture Titles: “Extracellular Matrix,” and “Integrins”

Two contact hours



1401-500-01: Research Methods and Career Development

UDC/Georgetown Master’s Program in Cancer Biology, Prevention, and

Control

Role: Lecturer/Discussion Leader

Lecture Title: “How to Read a Scientific Paper”

One contact hour

Number of students: 4


Riggins CV 5

Fall 2012

Spring 2012


Transformed Cell


Role: Co-Course Director and Lecturer

Lecture Title: “Growth Factors and their Receptors”

One contact hour for lecture, ~35 contact hours as co-course director


Overall Evaluation Score: 5 out of 5 for lecture; co-course director evaluation not conducted

CBIO 562: Molecular and Cell Biology – In Depth


Role: Faculty

No lecture: lead journal club-style discussion of recent paper

One contact hour





Role: Lecturer


Two contact hours




Transformed Cell



Lecture Title: “Biochemical principles of growth factor signaling”



Overall Evaluation Score: 4.81 out of 5 for course director role; 4.84 out of 5 for lecturer role

TBIO 510: Biochemistry for Cancer Research


Role: Lecturer

Lecture Title: “Oxidative metabolism, mitochondria, and reactive oxygen species,” and a second lecture on the practical application of these concepts in the laboratory

Two contact hours



TBIO 584: Intro to Tumor Biology


Riggins CV 6

Fall 2013

Spring 2013

Role: Lecturer

Lecture Title: Orphan Nuclear Receptors

0.5 contact hours





Role: Faculty


One contact hour





Role: Lecturer


Two contact hours




Transformed Cell



Lecture Title: “Biochemical principles of growth factor signaling”



Overall Evaluation Score: 4.94 out of 5 for course director role; 4.91 out of 5 for lecturer role



Role: Lecturer


Three contact hours





Role: Lecturer

Lecture Title: Orphan Nuclear Receptors

0.5 contact hours



Riggins CV 7

Fall 2014

Spring 2014

Spring 2015



Role: Faculty


One contact hour





Role: Lecturer


Two contact hours




Transformed Cell



Lecture Title: “Biomolecular Interactions”



Overall Evaluation Score: 4.8 out of 5 for course director role; TBD for lecturer role



Role: Lecturer


Three contact hours


Overall Evaluation Score: TBD



Role: Lecturer

Lecture Title: Targeting ETS Family Transcription Factors in Triple

Negative Breast Cancer

0.5 contact hours





Role: Faculty

Riggins CV 8


One contact hour



Undergraduate Courses

Spring 2004



Role: Lecturer

Lecture Titles: “Extracellular Matrix,” “Integrins,” and

Three contact hours



BIOL 395: Topics in Cancer Causes and Prevention

Undergraduate course, University of the District of Columbia,

Washington, DC

Role: Lecturer

Lecture Title: “Phytoestrogens, Hormone Replacement and Oral

Contraceptives”

Two contact hours



Fall 2005,2006,2008 BIOL 495: Cellular and Molecular Aspects of the Transformed Cell

Undergraduate course, University of the District of Columbia,

Washington, DC

Role: Lecturer

Lecture Titles: “Growth Factors, Receptors, and Signal Transduction I and II”

Four contact hours (two hours per lecture)



Summer 2006 – 2010, 2014 Brown Bag Seminar Series (for summer research students)


Role: Lecturer

Lecture Titles: “Apoptosis, Cell Survival, and Cancer,” “Nuclear

Receptors and Cancer”

One contact hour


Overall Evaluation Score: N/A

MENTORING

Undergraduate Students

Riggins CV 9

Jonathan Roberts: I mentored Jon during the 2003-2004 academic year as he completed his Biology

Department undergraduate Senior Thesis entitled “Retinoid Resistance in Breast Cancer” in Dr. Robert

Clarke’s lab. This included training him in new laboratory techniques, teaching him how to interpret data, and guiding him in writing the thesis. Jon graduated from Georgetown in 2004, worked as a technician in Dr. Clarke’s lab for one year, then entered medical school at Temple University in the fall of 2005.

Haniee Chung: I mentored Haniee from January 2004 through May of 2005, during which time she began and completed her Biology Department undergraduate Senior Thesis entitled “The Role of

Interferon Regulatory Factor-1 in Breast Cancer Cell Response to Antiestrogens” in Dr. Robert

Clarke’s lab. In addition to developing strong skills in several laboratory techniques, data interpretation, and scientific writing, Haniee orally presented her work and was a finalist in the Student

Division of the 2005 Student Research Days Competition, sponsored by the Office of Biomedical

Graduate Education. Haniee is a co-author on a paper published in Molecular Cancer Therapeutics in

2010. Haniee graduated from Georgetown in May 2005, worked for one year as a research assistant in the Department of Neurology at Johns Hopkins University, and entered Georgetown School of

Medicine in the fall of 2006. She is now in the General Surgery residency program at Washington

University of St. Louis.

Jennifer Pei-Jen Lan: I mentored Jennifer from January through August 2005, before she began a yearlong study abroad program at Oxford University in the U.K. Jenn then rejoined the lab for the

2006-2007 academic year in order to complete her Biology Department undergraduate Senior Thesis, where she investigated the role of estrogen-related receptor gamma (ERRγ) in estrogen dependence and antiestrogen resistance. She is second-author on our 2008 Cancer Research publication. Jen graduated from Georgetown in May 2007 and entered Georgetown School of Medicine in the fall of

2007. She is currently an Allergy/Immunology Fellow at the University of Tennessee Health Science

Center in Memphis, TN.

Jennifer Mulla: Jennifer was a Human Biology major in the School of Nursing and Health Sciences.

She began working with me in Dr. Clarke’s lab during the spring semester of 2006, studying the molecular mechanism(s) of apoptosis that are regulated by Interferon Regulatory Factor-1, and she is a co-author our 2010 Molecular Cancer Therapeutics paper. During her junior year (2007), Jenn received the Charles H. Evans, Jr. Award for best poster presentation at the Georgetown University

Undergraduate Research Conference; in her senior year, she received this award again for the best oral presentation. Jenn received her degree in May 2008, was accepted into the NIH Post baccalaureate

IRTA program in the laboratory of Dr. Douglas Lowy, and entered medical school at Eastern Virginia

Medical School in 2010. She is now in the Pediatric residency program at Children’s Hospital of The

King’s Daughters in Norfolk, VA.

Omar Maniya: Omar was a Biology major who began working in the lab as a sophomore during the spring semester of 2009 in preparation for his undergraduate Senior Thesis work. He studied the role of orphan nuclear receptors in multiple models of Tamoxifen resistance. Omar was accepted into

Georgetown School of Medicine’s Early Assurance Program during his sophomore year, and he is a co-author on our review of orphan nuclear receptors in breast cancer published in Endocrine-Related

Riggins CV 10

Cancer (2010). Omar entered Georgetown School of Medicine in the fall of 2011, and is part of the dual-degree MD/MBA program.

Loubna Elhelu: Loubna was a Biology major at the University of the District of Columbia who worked in my lab for one year during her sophomore year (2009-2010). In collaboration with Dr. Deepak

Kumar (Associate Professor at UDC with a joint appointment to the Department of Oncology at

Georgetown), Loubna studied the role of the endocrine disruptor Bisphenol A in regulating growth and gene expression in normal mammary epithelial cells.

Sara Alnoor: Sara was a Biology major at George Mason University. Sara performed an independent study in my lab during the 2011-2012 academic year, where she studied the regulation of cell migration and adhesion by the orphan nuclear receptors ERR



and ERR



in glioblastoma. She is currently an embryology lab assistant at Shady Grove Fertility.

Alex Farzanegan: Alex is a rising sophomore at Penn State University, and worked in my lab for the summer months of 2014 through the LCCC Summer Research Volunteer Program. Working together with my former graduate student and postdoctoral fellow Mary Heckler, Alex studied DY131/ERRβ signaling in triple negative breast cancer.

MS Students

Cara Schafer: Cara was a Master’s student in the Department of Biochemistry and Molecular Biology.

During the 2009-2010 academic year, Cara performed her internship in my lab during the spring semester, where she studied the combined effects of a high fat diet and neonatal BPA exposure on measures of Type 2 diabetes and insulin resistance in female rodents. Cara then joined my lab as a fulltime Research Assistant from June 2010 through June 2011. She is currently a PhD candidate in the

Cancer Biology Graduate Program at the University of Alabama-Birmingham. Cara is a co-author on our FEBS Journal publication (2014).

Pharah Morgan: Pharah was a Master’s student in the Tumor Biology Program in the Department of

Oncology, and among the first in the program’s new Cancer Systems Biology Track. She performed her Spring 2013 internship in my lab from January through April 2013, where her work focused on mapping and screening putative target genes of ERR



in ER+, endocrine resistant breast cancer.

Pharah went on to obtain a Master’s of Public Health at the University of Arizona, and she is now a

Health Program Manager at the Navajo County Department of Public Health in Holbrook, AZ.

Tizita Zeleke: Tizita was a Master’s student in the Tumor Biology Program, Cancer Systems Biology

Track, in the Department of Oncology. She began her internship in my lab in October 2013, where she remained until April 2014. Tizita studied the role of DY131/ERRβ signaling in triple negative breast cancer in African American women. Tizita worked as a patient navigator at the Capital Breast Care

Center in Washington, DC for one year before joining the PhD program at Mt. Sinai in the summer of

2015.

Nataly Naser Al Deen: Nataly is a Master’s student in the Tumor Biology Program in the Department of Oncology. She began her internship in my lab in October 2014, where she studied the functional interaction between the tumor suppressor p53 and inhibition of ETS family function by the small

Riggins CV 11

molecule YK-4-279. Nataly joined the PhD program in Cell and Molecular Biology at the American

University of Beirut in the summer of 2015.

Catherine Aldrich: Catherine is a Master’s student in the Tumor Biology Program in the Department of

Oncology. She began her internship in my lab in October 2014, where she helped to analyze the function of the ERRβ2 splice variant carboxyl-terminus. Catherine is currently a Biomarker Scientist at

Pfizer.

PhD and Medical Students

Bianca Gomez: Bianca was a graduate student at Howard University who performed her graduate work in Dr. Clarke’s laboratory and defended her thesis in July 2006. Beginning in July of 2003, I worked with Bianca toward the completion of her thesis project, which focuses on understanding what role the hXBP-1 gene plays in antiestrogen-resistant breast cancer. Bianca and I are co-authors on a publication in the FASEB Journal (2007). Bianca is currently a postdoctoral fellow at the NIH.

Ruchi Nehra: Ruchi was a Tumor Biology Ph.D. student in Dr. Robert Clarke’s laboratory. I played an integral role in mentoring Ruchi during her thesis work, in which she investigated the role of NFkappaB in endocrine resistance. She and I are co-authors on publications in Molecular Cancer

Therapeutics (2005), the Journal of Steroid Biochemistry and Molecular Biology (2009), and the

FASEB Journal (2010). She successfully defended her thesis in early December 2009.

Anatasha Crawford: Tasha was a Tumor Biology Ph.D. student in Dr. Robert Clarke’s laboratory.

With my guidance, she developed a research proposal that was successfully funded through a DoD

Pre-Doctoral Fellowship (BC050389), in which she studied the involvement of the pro-survival molecule Bcl-2 in antiestrogen resistance. We are co-authors on publications in the FASEB Journal

(2007; 2010), the Journal of Steroid Biochemistry and Molecular Biology (2009), and PloS ONE

(2010). Tasha successfully defended her thesis in September 2009, then completed the Fellowship In

Research and Science Teaching (FIRST) postdoctoral training program at Emory University. Tasha recently completed her MPH at Emory University, with a focus on Behavioral Sciences and Health

Education. She is now a clinical research coordinator at Emory University.

Nesrin Rechache: A graduate student in the Department of Physiology & Biophysics, Nesrin joined

Dr. Clarke’s laboratory in the spring of 2006. I assisted Nesrin with her thesis work, which focuses on molecular mechanisms of resistance to cytotoxic agents, particularly the taxanes. Her thesis proposal was also funded through the DoD Pre-Doctoral Fellowship program. Nesrin successfully defended her thesis in June 2010, performed a postdoctoral fellowship at the NIH, and now works in Technical and

Marketing Communications for QIAGEN.

Stefan Wallin: Stefan was a medical student at Linköping University in Sweden. He came to the

Lombardi Comprehensive Cancer Center for a 10 week internship/laboratory practicum in the Spring of 2009, where he worked with me on two projects studying the role of Bisphenol A exposure in affecting (1) Tamoxifen resistance in ER+ breast cancer, and (2) obesity, Type 2 diabetes, and insulin resistance in rodents.

Riggins CV 12

Jessica L. Schwartz Roberts: Jessica was a graduate student in the Department of Physiology &

Biophysics who is mentored by Dr. Robert Clarke. I helped Jessica draft the career development portion of her NIH F32 individual fellowship, funded in Spring 2012, which focuses on the role of

IRF1 in regulating breast cancer response to cytotoxic chemotherapies. We are also collaborating with

Drs. Bassem Haddad and Bhaskar Kallakury (GUMC) on a project examining the expression of IRF1 in familial breast cancer. Jessica successfully defended her thesis in 2013. She is now a Technical

Specialist at the law firm of Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. We are coauthors on a manuscript recently published in Cancer Research (2015).

Rochelle Nasto: Rochelle is a graduate student at the Drexel University School of Biomedical

Engineering, Science, and Health Systems. However, her thesis research is carried out at partly at

Georgetown University (with Dr. Louis Weiner) and partly at the Fox Chase Cancer Center (with Dr.

Erica Golemis). In connection with U54 CA149147-01, I have mentored Rochelle in aspects of her research that relate to estrogen independence in breast cancer cells. I have also met with Rochelle concerning career development and obtaining a postdoctoral fellowship. We are co-authors on a manuscript published in 2015 in Oncogene .

Mary Mazzotta Heckler: My first graduate trainee, Mary recently completed her Tumor Biology PhD in the Department of Oncology. Mary is second-author on our review of orphan nuclear receptors in breast cancer published in Endocrine-Related Cancer (2010), first-author of our FEBS Journal manuscript (2014), and first-author on a manuscript published in Cell Cycle (2015) that describes her thesis research, which focused on the function of ERRβ in glioblastoma cell death and cell cycle control. From 2012-2014, Mary was supported by LCCC’s Postbaccalaureate Training in Disparities

Research grant awarded by Susan G. Komen for the Cure. She was also a laboratory mentor for Tizita

Zeleke and Steve DeVito in their work on ERRbeta in triple negative breast cancer. Completing her

PhD in four years, Mary successfully defended her thesis on April 25 th

, 2014 and remained in my laboratory as a postdoctoral fellow through September 2014. Mary is currently a Medical Writer at

Medpace in Cincinnati, OH.

Ziling Fan: Ziling is a 3 rd

year PhD student in the Biochemistry graduate program, and was a rotating student in my lab from February through May 2013. He studied the role of ERR



posttranslational modification in breast cancer. He is now a PhD student in the laboratory of Dr. Al Fornace.

Stephen DeVito: Steve is a 2 nd

year PhD student in the Tumor Biology Training Program. During his

1 st

year, Steve rotated through my lab from August through December 2013, where he investigated

DY131/ERRβ signaling in triple negative breast cancer. He is currently a PhD student in the laboratory of Dr. Rabindra Roy.

Deanna M. Tiek: Deanna is a 1 st

year PhD student in the Tumor Biology Training Program. She began her rotation in my laboratory in September 2014, where her project is to study interactions between

ERRβ splice variants and cortactin in models of glioblastomas and triple negative breast cancer.

Aileen Fernandez: Aileen is a 1 st

year PhD student in the Tumor Biology Training program. She began her rotation in my laboratory in January 2015, where she is examining the role of ERRβ2 in mitotic arrest in triple negative breast cancer cells.

Riggins CV 13

Lama Alhawas: Lama is a 1 st

year student in the Biochemistry graduate program, and began her rotation in my lab in January 2015. Her rotation project is focused on determining whether the ETS family inhibitor YK-4-279 is efficacious in triple negative breast cancer. She is now a PhD student in the laboratory of Dr. Richard Schlegel.

Postdoctoral Fellows

Yanxia Ning: Yanxia was a member of Dr. Clarke’s laboratory from Fall 2007 through Fall 2009. She came to the group as a China Scholarship Council postdoctoral fellow to study the regulation of IRF1 in breast cancer and its modulation of breast cancer responsiveness to endocrine therapy. I helped

Yanxia to focus and develop her studies, and we are co-authors on a paper that was published by

Molecular Cancer Therapeutics in 2010. Yanxia is currently a fellow in the Department of

Physiology and Pathophysiology at Shanghai Medical College, Fudan University, China.

Rong Hu: Rong joined Dr. Clarke’s laboratory in January 2010 as a postdoctoral fellow, after receiving her PhD from Thomas Jefferson University. Rong was awarded a DoD Post-Doctoral Fellowship application that focuses on studying the role of NFkB in XBP1-mediated endocrine resistance, and I assisted her in crafting her training and career development plan for this application. We are co-authors on a manuscript published in Molecular and Cellular Biology in 2014 that reports the findings of her fellowship-funded research.

Kedra Cyrus: Kedra is a 4 th

year postdoctoral fellow, formerly supported by LCCC’s T32 Tumor

Biology Training Grant, in the laboratory of Dr. Mary Beth Martin. I am on her fellowship advisory committee.

Shailaja Divekar: Shailaja is a postdoc in my lab, where she is studying the physical and functional interactions of cortactin with ERRβ splice variants.

Junior Faculty

Geeta Upadhay: Geeta is currently a Research Assistant Professor in the Department of Oncology. I have met with Geeta on several occasions to share my experience(s) with transitioning to an independent faculty position. I also introduced Geeta to scientific review staff for the Department of

Defense Breast Cancer Research Program (DoD BCRP), so that she might have the opportunity to serve on study section. Geeta has since participated on several review panels for the DoD.

Thesis Committees

* denotes committee chair

Allison Sumis: Allison was a Tumor Biology PhD student in the laboratory of Dr. Leena Hilakivi-

Clarke. She successfully defended her thesis in April 2014.

* Tsion Minas: Tsion is a 3 rd

year graduate student in the Tumor Biology PhD program in the laboratory of Dr. Aykut Üren.

Riggins CV 14

Nguyen Nguyen: Nguyen is a 4 th

year graduate student in the Tumor Biology PhD program in the laboratory of Dr. Leena Hilakivi-Clarke.

Eric Berens: Eric is a 3 rd

year graduate student in the Tumor Biology PhD program in the laboratory of

Dr. Anton Wellstein.

* Brian Duchez: Brian is a 3 rd

year PhD student in the Georgetown University/National Institutes of

Health Graduate Program in Biomedical Sciences in the laboratory of Dr. Kenneth Yamada (NIDCR).

*Naiem Issa: Naiem is an MD/PhD student at Georgetown University, and performed his thesis research in the laboratory of Dr. Stephen Byers. He successfully defended his thesis in June 2015.

Sahar Alothman: Sahar is a 2 nd

year PhD student in the Tumor Biology PhD program in the laboratory of Dr. Priscilla Furth.

COLLABORATIVE ACTIVITIES

Joint Grants

Joint, funded grant applications with other GUMC faculty since last appointment/promotion.

R01 CA149653 *Xuan (PI); Riggins (Co-investigator) 3/2011 – 2/2013

National Institutes of Health (NCI) $85,000 (subcontract annual direct costs) 0.6 cal. mos.

“Uncovering estrogen receptor signaling networks to overcome endocrine resistance.”

*Dr. Jianhua Xuan is the overall PI (VA Tech). Dr. Robert Clarke and I were co-investigators on a sub-contract for this grant.

Intramural Award Riggins/Martin (coPIs) 6/2013 – 5/2014

Nina Hyde Center $25,000 no salary

“

Nitrite – a Novel Estrogen-related Receptor Ligand that Drives Metabolic Reprogramming in Breast

Cancer and Cachectic Muscle

”

R21 CA191444 Riggins (PI)^

National Institutes of Health (NCI) $427,625

“

Mitotic regulation by the ERRβ2 splice variant

”

^ Dr. Susette Mueller is a co-investigator on this grant.

Intramural Award Riggins (PI) ^

Nina Hyde Center $25,000

“ Targeting Triple Negative Breast Cancer: ETS Happening Now!”

^ Drs. Luciane Cavalli and Jeffrey Toretsky are co-investigators on this grant.

9/2014 – 8/2016

3.0 cal. mos.

9/2014 – 8/2015 no salary

Joint Publications

Joint publications with other GUMC faculty since last appointment/promotion.

Clarke R, Shajahan AN, Wang Y, Tyson JJ, Riggins RB , Weiner LM, Baumann WT, Xuan J, Zhang

B, Facey C, Aiyer H, Cook K, Hickman FE, Tavassoly I, Verdugo A, Chen C, Zwart A, Warri A, and

Hilakivi-Clarke LA. Endoplasmic reticulum stress, the unfolded protein response, and gene network

Riggins CV 15

modeling in antiestrogen resistant breast cancer. Hormone Molecular Biology and Clinical

Investigation , 5: 35-44 (2011).

*Gong T, Xuan J, Chen L, Riggins RB , Li H, Hoffman EP, Clarke R, and Wang Y. Motif-guided sparse decomposition of gene expression data for regulatory module identification. BMC

Bioinformatics , 12: 82 (2011). *Designated as “Highly Accessed” by BioMed Central.

*Chen L, Xuan J, Riggins RB , Clarke R, and Wang Y. Identifying cancer biomarkers by networkconstrained support vector machines. BMC Systems Biology , 5: 161 (2011). *Designated as “Highly

Accessed” by BioMed Central.

Madhavan S, Gusev Y, Harris M, Tanenbaum DM, Gauba R, Bhuvaneshwar K, Shinohara A, Rosso

K, Carabet L, Song L, Riggins RB , Dakshanamurthy S, Wang Y, Byers S, Clarke R, and Weiner LM.

G-DOC: A Systems Medicine Platform for Personalized Oncology. Neoplasia , 13: 771-83 (2011).

Gu J, Xuan J, Riggins RB , Chen L, Wang Y, and Clarke R. Robust identification of transcriptional regulatory networks using a Gibbs sampler on outlier sum statistic. Bioinformatics , 28: 1990-7 (2012).

Yenugonda VM, Kong Y, Yang Y, Riggins RB , and Brown ML. Trans-resveratrol boronic acid exhibits enhanced anti-proliferative activity in estrogen-dependent MCF-7 breast cancer cells. Cancer

Biology and Therapy , 13: 925-34 (2012).

Chen L, Xuan J, Riggins RB , Wang Y, and Clarke R. Identifying protein interaction subnetworks by a bootstrapping Markov random field-based method. Nucleic Acids Research , 41: e42 (2013).

Gusev Y*, Riggins RB *, Bhuvaneshwar K, Gauba R, Sheahan L, Clarke R, and Madhavan S. In silico discovery of mitosis regulation networks associated with early distant metastases in estrogen receptor positive breast cancers. Cancer Informatics , 12: 31-51 (2013). *equal contribution.

Chen X, Xuan J, Wang C, Shajahan AN, Riggins RB , and Clarke R. Reconstruction of transcriptional regulatory networks by stability-based network component analysis. IEEE/ACM Trans Comput Biol

Bioinform , 10: 1347-58 (2013).

Hu R, Warri A, Jin L, Zwart A, Riggins RB , Fang H, and Clarke R. NFκB signaling is required for

XBP1 (U and S) mediated effects on antiestrogen responsiveness and cell fate decisions in breast cancer. Molecular and Cellular Biology , 35: 379-90 (2015). Epub 2014 Nov 3.

Madhavan S, Gusev Y, Singh S, and Riggins RB . ERRγ target genes are poor prognostic factors in

Tamoxifen-treated breast cancer. Journal of Experimental and Clinical Cancer Research , 34: 45

(2015).

Zhang Y-W, Nasto RE, Varghese R, Jablonski SA, Serebriiskii IG, Surana R, Calvert VS, Bebu I,

Murray J, Jin L, Johnson MD, Riggins RB , Ressom H, Petricoin E, Clarke R, Golemis EA, and

Weiner LM. Acquisition of estrogen independence induces TOB1-related mechanisms supporting breast cancer cell proliferation. Oncogene , accepted (2015).

Roberts JL, Cook KL, Chen C, Shajahan-Haq AN, Axelrod M, Warri A, Riggins RB , Jin L, Haddad

BR, Kallakury B, Baumann WT, and Clarke R. Interferon regulatory factor-1 signaling regulates the

Riggins CV 16

switch between autophagy and apoptosis to determine breast cancer cell fate. Cancer Research , 75: 1-

10 (2015).

SCHOLARSHIP AND RESEARCH

R ESEARCH G RANTS

Current Active

PBTDR12228366

Susan G. Komen for the Cure

Adams-Campbell (PI); Riggins (mentor) 9/2012 – 8/2016*

$405,000

“Postbaccalaureate training in breast cancer health disparities.”

PhD trainee stipend

*2016-2020 renewal has been selected for funding.

R21 CA191444 Riggins (PI)

NIH/NCI $427,625

“

Mitotic regulation by the ERRbeta2 splice variant

”

Intramural Award Riggins (PI)

LCCC CCSG developmental funds $25,000

“

ERRbeta2: novel mediator of centrosome declustering

”

9/2014 – 8/2016

3.0 cal. mos.

7/2015 – 6/2016 no salary

Current Pending

R01 CA196841 Riggins (PI)

NIH/NCI $288,635 annual direct costs

“

ERRbeta splice variant functions and interactions in cancer biology

”

4/2016 – 3/2021

4.2 cal. mos.

Previous

Postdoctoral Fellowship

Ladies Auxiliary to the VFW

Riggins (PI)

Cancer Research Fellowship

“Role of IRF-1 in Breast Cancer Antiestrogen Resistance.”

$50,000 annual direct costs

PDF0503551 Clarke (PI); Riggins (Fellow)

7/2004 – 6/2005

12 cal. mos.

Susan G. Komen for the Cure $45,000 annual direct costs

5/2005 – 4/2007

12 cal. mos.

Postdoctoral Fellowship

“IRF-1-dependent apoptosis and antiestrogen sensitivity in breast cancer”

BC051851 Riggins (PI) 9/2006 – 9/2007

Department of Defense BCRP $75,000 annual direct costs 12 cal. mos.

“ERR Gamma: Does an Orphan Nuclear Receptor Link Steroid Hormone Biogenesis to Endocrine

Resistance?”

IRG97-152-16

American Cancer Society

Riggins (PI)

$20,000 annual direct costs

Institutional Research Grant Young Investigator Award

8/2008 – 7/2009

No salary

Riggins CV 17

“Exposure to the endocrine disruptor Bisphenol A induces Tamoxifen resistance in ER+ breast cancer through transcriptional activation of estrogen related receptor gamma.”

Research Award Kumar (PI); Riggins (CoI) 3/2009 – 2/2010

USDA/University of DC Agricultural Extension Service $15,000 No salary

“The effects of Bisphenol A, an endocrine-disrupting pollutant, on mammalian cells: a genomic study.”

R03 CA142009 Riggins (PI) 7/2009 – 6/2012

NIH/NCI Cancer Prevention R03 $50,000 annual direct costs 1.2 cal. mos.

“ERRgamma-dependent mammary tumorigenesis in response to BPA and a high-fat diet.”

KG090187

Susan G. Komen for the Cure

Riggins (PI) 4/2009 – 4/2013

$119,764 annual direct costs 6.0 cal mos.

Career Catalyst Research Grant

“Regulation of ERRgamma in endocrine resistant breast cancer by the ERK pathway.”

Intramural Award Riggins (PI) 11/2012 – 6/2

No salary Partners In Research $35,000

“ Therapeutic targeting of p53-mutant tumors with the acyl hydrazone DY131 ”

12ST1101 Clarke/Madhavan (co-PIs); Riggins (Co-Investigator) 12/2012 – 9/2013

NIH/NCI $544,307 annual direct costs

“Cancer Bioinformatics Grid (caBIG) In Silico Research Center (ISRCE).”

3.6 cal. mos.

Intramural Award Riggins/Martin (coPIs) 6/2013 – 5/2014

Nina Hyde Center $25,000 No salary

“ Nitrite – a Novel Estrogen-related Receptor Ligand that Drives Metabolic Reprogramming in Breast

Cancer and Cachectic Muscle

”

U54 CA149147-01 Clarke (PI); Riggins (Co-Investigator) 7/2010 – 2/2015

NIH/NCI $1.5 million annual direct costs

“Endocrine responsiveness and cellular stress.”

Intramural Award Riggins (PI)

Nina Hyde Center $25,000

“ Targeting Triple Negative Breast Cancer: ETS Happening Now!”

1.2 cal. mos.

9/2014 – 8/2015 no salary

P UBLICATIONS

Original Papers in Refereed Journals

Riggins RB , DeBerry RM, Toosarvandani MD, and Bouton AH. Association of Cas and

Phosphatidylinositol 3-kinase (PI3K) in crk -transformed cells. Molecular Cancer Research , 1: 428-

37 (2003).

Riggins RB , Quilliam LA, and Bouton AH. Synergistic promotion of c-Src activation and cell migration by Cas and AND-34/BCAR3. J. Biological Chemistry , 278(30): 28264-73 (2003).

Riggins CV 18

Bouker KB, Skaar TC, Fernandez DR, O’Brien KA,

Riggins RB , Cao D and Clarke R. Interferon regulatory factor-1 regulates the proapoptotic but not cell cycle arrest effects of the steroidal antiestrogen ICI 182,780 (Faslodex, Fulvestrant). Cancer Research , 64: 4030-39 (2004).

Riggins RB

, Zwart A, Nehra R, and Clarke R. The NFκB inhibitor parthenolide restores ICI 182,780

(Faslodex; Fulvestrant)-induced apoptosis in antiestrogen-resistant breast cancer cells. Molecular

Cancer Therapeutics , 4: 33-41 (2005).

Bouker KB, Skaar TC, Riggins RB, Harburger DS, Fernandez DR, Zwart A, Wang A, and Clarke R.

Interferon regulatory factor-1 (IRF-1) exhibits tumor suppressor activities in breast cancer associated with caspase activation and induction of apoptosis. Carcinogenesis , 26: 1527-35 (2005).

*Riggins RB, Thomas KS, Ta HQ, Wen J, Davis RJ, Schuh NR, Donelan SS, Owen KA, Gibson MA,

Shupnik MA, Silva CM, Parsons SJ, Clarke R, and Bouton AH. Physical and functional interactions between Cas and c-Src induce Tamoxifen resistance of breast cancer cells through EGFR and

STAT5b. Cancer Research , 66:7007-15 (2006). * article was featured in Cancer Research Highlights.

Bouker KB, Skaar TC, Harburger DS, Riggins RB , Fernandez DR, Zwart A, Clarke R. The A4396G

Polymorphism in Interferon Regulatory Factor-1 is Frequently Expressed in Breast Cancer Cell Lines.

Cancer Genetics and Cytogenetics , 175:61-4 (2007).

Schrecengost RS, Riggins RB , Thomas KS, Guerrero MS, and Bouton AH. BCAR3 expression regulates breast cancer cell migration through promotion of p130Cas localization and membrane ruffling. Cancer Research , 67:6174-82 (2007).

Gomez BP, Riggins RB , Shajahan AN, Klimach U, Wang A, Crawford AC, Zhu Y, Zwart A, Wang

M, and Clarke R. Human X-box binding protein-1 confers both estrogen-independence and antiestrogen resistance in breast cancer cell lines. FASEB Journal , 21:4013-27 (2007).

*^Riggins RB , Lan JP, Zhu Y, Klimach U, Zwart A, Cavalli LR, Haddad BR, Chen L, Gong T, Xuan

J, Ethier SP, and Clarke R. ERRγ mediates Tamoxifen resistance in novel models of invasive lobular cancer. Cancer Research , 68: 8908-17 (2008). * article was featured in Cancer Research

Highlights.

^ Corresponding author.

Zhang B, Li H, Riggins RB , Zhan M, Xuan J, Zhang Z, Hoffman EP, Clarke R, and Wang Y.

Differential dependency network analysis to identify condition-specific topological changes in biological networks. Bioinformatics , 25: 526-32 (2009).

Chen L, Xuan J, Wang Y, Hoffman EP, Riggins RB , and Clarke R. Identification of Conditionspecific Regulatory Modules by Multi-level Motif and mRNA Expression Analysis. Intl J

Computational Biology and Drug Design , 2: 1-20 (2009).

Cavalli LR, Riggins RB , Wang A, Clarke R, and Haddad BR. Frequent loss of heterozygosity at the

Interferon Regulatory Factor-1 (IRF-1) gene locus in breast cancer. Breast Cancer Res Treat , 121:

227-31 (2010).

Riggins CV 19

Nehra R, Riggins RB , Shajahan AN, Zwart A, Crawford AC, and Clarke R. BCL2 and CASP8 regulation by NF



B differentially affect mitochondrial function and cell fate in antiestrogen sensitive and resistant breast cancer cells. FASEB Journal , 24: 2040-55 (2010).

Crawford AC, Riggins RB , Shajahan AN, Zwart A, and Clarke R. Co-inhibition of BCL-W and BCL-

2 restores antiestrogen sensitivity through BECN1 and promotes an autophagy-associated necrosis.

PloS ONE , 5(1): e8604 (2010).

*Ning Y, Riggins RB , Mulla JE, Chung H, Zwart A, and Clarke R. Interferon gamma restores breast cancer sensitivity to Fulvestrant by regulating STAT1, IRF1, NF



B, specific BCL2 family members, and signaling to caspase-dependent apoptosis. Molecular Cancer Therapeutics , 9: 1274-85 (2010).

*article was featured on the cover of the May 2010 issue.

Chen L, Xuan J, Riggins RB , Wang Y, Hoffman EP, and Clarke R. Multi-level motif and mRNA expression analysis to identify condition-specific regulatory modules. Bioinformatics , 26; 1416-22

(2010).

* Broustas C, Ross J, Yang Q, Sheehan C, Riggins RB , Noone A, Haddad BR, Sellier-Moiseiwitsch F,

Kallakury B, Haffty B, Clarke R, and Kasid U. The pro-apoptotic molecule BLID interacts with BclxL and its downregulation in breast cancer correlates with poor disease free and overall survival.

Clinical Cancer Research , 16: 2939-49 (2010). * article was featured on the cover of the June 2010 issue.

*Gong T., Xuan J, Chen L, Riggins RB , Li H, Hoffman EP, Clarke R, and Wang Y. Motif-guided sparse decomposition of gene expression data for regulatory module identification. BMC

Bioinformatics , 12: 82 (2011). *Designated as “Highly Accessed” by BioMed Central.

*Chen L, Xuan J, Riggins RB , Clarke R, and Wang Y. Identifying cancer biomarkers by networkconstrained support vector machines. BMC Systems Biology , 5: 161 (2011). *Designated as “Highly

Accessed” by BioMed Central.

Madhavan S, Gusev Y, Harris M, Tanenbaum DM, Gauba R, Bhuvaneshwar K, Shinohara A, Rosso

K, Carabet L, Song L, Riggins RB , Dakshanamurthy S, Wang Y, Byers S, Clarke R, and Weiner LM.

G-DOC: A Systems Medicine Platform for Personalized Oncology. Neoplasia , 13: 771-83 (2011).

Gu J, Xuan J, Riggins RB , Chen L, Wang Y, and Clarke R. Robust identification of transcriptional regulatory networks using a Gibbs sampler on outlier sum statistic. Bioinformatics , 28: 1990-7 (2012).

Yenugonda VM, Kong Y, Yang Y, Riggins RB , and Brown ML. Trans-resveratrol boronic acid exhibits enhanced anti-proliferative activity in estrogen-dependent MCF-7 breast cancer cells. Cancer

Biology and Therapy , 13: 925-34 (2012).

Chen L, Xuan J, Riggins RB , Wang Y, and Clarke R. Identifying protein interaction subnetworks by a bootstrapping Markov random field-based method. Nucleic Acids Research , 41: e42 (2013).

Gusev Y*, Riggins RB *, Bhuvaneshwar K, Gauba R, Sheahan L, Clarke R, and Madhavan S. In silico discovery of mitosis regulation networks associated with early distant metastases in estrogen receptor positive breast cancers. Cancer Informatics , 12: 31-51 (2013). *equal contribution.

Riggins CV 20

Chen X, Xuan J, Wang C, Shajahan AN, Riggins RB , and Clarke R. Reconstruction of transcriptional regulatory networks by stability-based network component analysis. IEEE/ACM Trans Comput Biol

Bioinform , 10: 1347-58 (2013).

Heckler MM, Thakor H, Schafer CC, and Riggins RB . ERK/MAPK regulates ERRγ expression, transcriptional activity, and receptor-mediated Tamoxifen resistance in ER+ breast cancer. FEBS

Journal , 281: 2431-42 (2014).

Heckler MM and Riggins RB

. ERRβ splice variants differentially regulate cell cycle progression.

Cell

Cycle , Epub ahead of print (2014).

Hu R, Warri A, Jin L, Zwart A, Riggins RB , Fang H, and Clarke R. NFκB signaling is required for

XBP1 (U and S) mediated effects on antiestrogen responsiveness and cell fate decisions in breast cancer. Molecular and Cellular Biology , 35: 379-90 (2015). Epub 2014 Nov 3.

Madhavan S, Gusev Y, Singh S, and Riggins RB

. ERRγ target genes are poor prognostic factors in

Tamoxifen-treated breast cancer. Journal of Experimental and Clinical Cancer Research , 34: 45

(2015).



Weiner LM. Acquisition of estrogen independence induces TOB1-related mechanisms supporting breast cancer cell proliferation. Oncogene , accepted (2015).

Roberts JL, Cook KL, Chen C, Shajahan-Haq AN, Axelrod M, Warri A, Riggins RB , Jin L, Haddad

BR, Kallakury B, Baumann WT, and Clarke R. Interferon regulatory factor-1 signaling regulates the switch between autophagy and apoptosis to determine breast cancer cell fate. Cancer Research , 75: 1-

10 (2015).

Reviews or Editorials in Refereed Journals

Bouton AH, Riggins RB , and Bruce-Staskal PJ. Functions of the Adapter Protein Cas: Signal

Convergence and the Determination of Cellular Responses. Oncogene, 20: 6448-58 (2001).

Hilakivi-Clarke L, Wang C, Kalil M, Riggins R , and Pestell RG. Cell cycle control in breast cancer: the role of dietary intervention. Endocrine Related Cancer , 11 (4): 603-22 (2004).

Riggins RB , Schrecengost RS, Guerrero MS, and Bouton AH. Pathways to Tamoxifen Resistance.

Cancer Letters, 256: 1-24 (2007).

Clarke R, Shajahan AN, Riggins RB , Crawford AC, Xuan J, Wang Y, Zwart A, Nehra R, and Liu MC.

Gene network signaling in hormone responsiveness modifies apoptosis and autophagy in breast cancer cells. J Steroid Biochem Mol Biol , 114: 8-20 (2009).

Shajahan AN, Riggins RB , and Clarke R. The role of X-box binding protein-1 in tumorigenicity.

Drug News Perspect , 22: 241-6 (2009).

Riggins CV 21

Riggins RB . ESRRG (estrogen-related receptor gamma). Atlas Genet Cytogenet Haematol (October

2009). http://AtlasGeneticsOncology.org/Genes/ESRRGID45840ch1q41.html

Riggins RB , Mazzotta MM, Maniya OZ, and Clarke R. Orphan nuclear receptors in breast cancer pathogenesis and therapeutic response. Endocrine-Related Cancer , 17: R213-31 (2010).

Clarke R, Shajahan AN, Wang Y, Tyson JJ, Riggins RB , Weiner LM, Baumann WT, Xuan J, Zhang

B, Facey C, Aiyer H, Cook K, Hickman FE, Tavassoly I, Verdugo A, Chen C, Zwart A, Warri A, and

Hilakivi-Clarke LA. Endoplasmic reticulum stress, the unfolded protein response, and gene network modeling in antiestrogen resistant breast cancer. Hormone Molecular Biology and Clinical

Investigation , 5: 35-44 (2011).

Riggins RB . The pERK of being a target: kinase regulation of the orphan nuclear receptor ERRγ.

Receptors & Clinical Investigation , 1: 253-57 (2014). doi: 10.14800/rci.207.

( http://www.smartscitech.com/index.php/rci/article/view/207 )

Books or Chapters in books, and publications in other journals

Riggins RB , Bouton AH, Liu MC, and Clarke R. Antiestrogens, aromatase inhibitors, and apoptosis in breast cancer. Vitamins and Hormones , 71:201-37 (2005).

Shajahan AN, Riggins RB , and Clarke R. Apoptosis, cell death, and breast cancer. Chapter 8 in

Breast Cancer: Prognosis, Treatment, and Prevention , 2 nd edition , edited by Jorge R. Pasqualini,

ISBN 978-142005872-7 (2008).

Abstracts

Riggins RB and Bouton AH. A role for p130Cas and c-Src in breast cancer progression. 17 th

Annual

Meeting on Oncogenes, Frederick, MD 2001.

Riggins RB and Bouton AH. Regulation of c-Src kinase activity by the carboxy terminus of Cas.

AACR Annual Meeting, San Francisco, CA 2002.

*Riggins RB , Quilliam LA, and Bouton AH. Synergistic promotion of c-Src activation and cell migration by Cas and AND-34/BCAR3. AACR Special Conference on Proteases, Extracellular

Matrix, and Cancer, Hilton Head, SC 2002. * abstract was selected for oral presentation.

Riggins RB , Schuh NR, Shupnik MA, Quilliam LA, and Bouton AH. Cas and AND-34 promote tamoxifen resistance and estrogen independence in MCF-7 breast cancer cells. 19 th

Annual Meeting on Oncogenes, Frederick, MD 2003.

Riggins RB

, Gomez BP, Zwart A, and Clarke R. NFκB signaling promotes antiestrogen resistance in

MCF-7 breast cancer cells. AACR Annual Meeting, Orlando, FL 2004.

Schuh NR, Riggins RB , Shupnik MA, Quilliam LA, and Bouton AH. Cas and AND-34 promote

Tamoxifen resistance and estrogen-independence in MCF-7 breast cancer cells. AACR Annual

Meeting, Orlando, FL 2004.

Riggins CV 22

Gomez BP, Riggins RB , Zhu Y, Zwart A, and Clarke R. Human X-box binding protein in antiestrogen resistance. AACR Annual Meeting, Orlando, FL 2004.

Khan GA, Olivo S, Riggins RB , and Hilakivi-Clarke L. Prepubertal N-3 PUFA diet alters the expression of PPARγ, cyclin D1, and ERα in the rat mammary gland. AACR Annual Meeting,

Orlando, FL 2004.

Bouker KB, Skaar TC, Riggins RB , Zwart A, Wang A, and Clarke R. IRF-1: a “new” tumor suppressor in breast cancer. 20 th

Annual Meeting on Oncogenes, Frederick, MD 2004.

Clarke R, Riggins RB , Bouker KB, Nehra R, Gomez BP, and Zwart A. Molecular mechanisms of endocrine resistance in breast cancer. 7 th

International Conference of Anticancer Research, Corfu,

Greece 2004.

Clarke R, Bouker KB, Riggins RB , and Skaar TC. Interferon regulatory factor-1 (IRF-1) as a novel tumor suppressor gene in breast cancer. 7 th

International Conference of Anticancer Research, Corfu,

Greece 2004.

Bouton AH, Riggins RB , Ta HQ, Thomas KS, Shupnik MA, and Silva CM. Src-Cas/BCAR1 interactions regulate estrogen dependence and antiestrogen resistance of breast cancer cells. Keystone

Symposia on Hormonal Regulation of Tumorigenesis, Monterey, CA 2005.

Riggins RB , Chung H, Roberts J, Zwart A, and Clarke R. The role of interferon regulatory factor-1

(IRF-1)-dependent apoptosis in breast cancer cell antiestrogen response. AACR Annual Meeting,

Anaheim, CA 2005.

Riggins RB , Bouker KB, Nehra R, Gomez BP, Zwart A, Zhu Y, and Clarke R. Molecular mechanisms of endocrine resistance in breast cancer. AACR Annual Meeting, Anaheim, CA 2005.

Riggins RB , Zwart A, Roberts J, Ethier SP, and Clarke R. SUM44-LCCTam: a new model of antiestrogen-resistant breast cancer. AACR Annual Meeting, Anaheim, CA 2005.

Bouker KB, Zhu Y, Riggins RB , Zwart A, Nehra R, Gomez BP, and Clarke R. Resistance to endocrine therapy in breast cancer. 4 th

Era of Hope Meeting, Philadelphia, PA 2005.

Nehra R, Riggins RB , Gomez BP, Zwart A, and Clarke R. Activation of NF-kappaB in breast cancer cells. 4 th


Gomez BP, Zhu Y, Riggins RB , Zwart A and Clarke R. X-box binding protein-1 in breast cancer. 4 th


Riggins RB, Thomas KS, Schuh NR, Donelan SS, Ta HQ, Owen KA, Gibson MA, Shupnik MA, Silva

CM, Parsons SJ, and Bouton AH. Physical and functional interactions between Cas and c-Src induce

Tamoxifen resistance of breast cancer cells through EGFR and STAT5b. AACR Special Conference on Advances in Breast Cancer: Genetics, Biology, and Clinical Applications, La Jolla, CA 2005.

Riggins RB , Zhu Y, Zwart A, Cho Y, Ethier SP, and Clarke R. Deregulation of ER-alpha, ERRgamma, and estrogen-regulated genes accompany endocrine resistance in a model of invasive lobular breast carcinoma. AACR Annual Meeting, Washington, DC 2006.

Riggins CV 23

Riggins RB

, Chung H, O’Brien KA, Crawford AC, Zwart A, and Clarke R. The role of IRF-1controlled apoptosis in breast cancer antiestrogen resistance. Mission Conference of the Susan G.

Komen Foundation, Arlington, VA 2006.

Riggins RB , Lan JP, Zwart A and Clarke R. Does the orphan nuclear receptor ERRγ link cholesterol synthesis to endocrine therapy resistance? AACR Annual Meeting, Los Angeles, CA 2007.

Crawford AC, Riggins RB , and Clarke R. The role of Bcl-2 in antiestrogen resistant breast cancer cells. AACR Annual Meeting, Los Angeles, CA 2007.

Rechache NS, Riggins RB , Zwart A and Clarke R. Molecular mechanisms of Taxane resistance.

AACR Annual Meeting, Los Angeles, CA 2007.

Gong T, Xuan J, Chen L, Riggins RB , Wang Y, Hoffman EP, and Clarke R. Sparse Decomposition of

Gene Expression Data to Infer Transcriptional Modules Guided by Motif Information. International

Symposium on Bioinformatics Research and Applications, Atlanta, GA 2008.

Chen L, Xuan J, Riggins RB , Wang Y, Hoffman EP, and Clarke R. Identification of conditionspecific regulatory modules by multi-level motif and mRNA expression analysis. International

Conference on Bioinformatics and Computational Biology (BIOCOMP'08), Las Vegas, NV 2008.

Gong T, Xuan J, Riggins RB , Wang Y, Hoffman EP, and Clarke R. Exploring Transcriptional

Modules by Integrative Gene Clustering Guided by Transcription Factor Binding Information.

International Conference on Bioinformatics and Computational Biology (BIOCOMP'08), Las Vegas,

NV 2008.

Riggins RB , Lan JP, Zwart A, and Clarke R. Regulation of orphan nuclear receptor ERRgamma action in endocrine-resistant breast cancer by the ERK signaling pathway. Keystone Symposia,

Nuclear Receptors: Orphan Brothers, Whistler, B.C., Canada 2008.

Mulla JE, Riggins RB , Zwart A, and Clarke R. The role of IRF1 in Fulvestrant-mediated apoptosis of

MCF7/LCC9 breast cancer cells. AACR Annual Meeting, San Diego, CA 2008.

Rechache NS, Riggins RB , Zwart A, and Clarke R. Mechanisms of cell death in acquired taxane resistance models. AACR Annual Meeting, San Diego, CA 2008.

Crawford AC, Riggins RB , and Clarke R. BCL2 family function in antiestrogen-resistant breast cancer cells. AACR Annual Meeting, San Diego, CA 2008.

Stoica A, Riggins RB , Abdallah A, Wang EP, Fox MD, Guerra R, Mautner LA, Summe HS, Zislis C, and Ressom H. Signaling networks of convergence of nongenomic and genomic estrogen actions mediated by Erbb2 and Akt1 in MCF-7 cells. AACR Annual Meeting, San Diego, CA 2008.

Riggins CV 24

Riggins RB , Lan JP, Zwart A, and Clarke R. ERRgamma: does an orphan nuclear receptor link steroid hormone biogenesis to endocrine resistance? 5 th

DoD Era of Hope Meeting, Baltimore, MD

2008.

Clarke R, Cho Y, Miller WR, Dixon JM, Xuan J, Riggins RB , Shajahan AN, Wang Y, and Liu MC.

Endocrine therapy of breast cancer. 5 th

DoD Era of Hope Meeting, Baltimore, MD 2008.

Nehra R, Riggins RB , and Clarke R. The NFkB inhibitor parthenolide restores sensitivity to 4hydroxytamoxifen through apoptotic pathways involving TNFR1 and Bcl-2 in antiestrogen-resistant

MCF-7 breast cancer cells. 5 th


Crawford AC, Riggins RB , and Clarke R. BCL2 family function in antiestrogen-resistant breast cancer cells. 5 th


Rechache NS, Riggins RB , Zwart A, and Clarke R. Mechanisms of cell death in acquired taxane resistance models. 5 th


Chen L, Xuan J, Wang Y, Riggins RB , and Clarke R. Network-constrained Support Vector Machine for Classification. 7 th

International Conference on Machine Learning and Applications, San Diego, CA

2008.

Rechache NS, Riggins RB , Zwart A, and Clarke R. Cell death mechanisms in acquired taxane resistance models. AACR Annual Meeting, Denver, CO 2009.

Ning Y, Riggins RB , Mulla JE, and Clarke R. Interferon gamma restores sensitivity to Faslodex in

MCF7/LCC9 breast cancer celsl by increasing IRF-1 expression. AACR Annual Meeting, Denver, CO

2009.

Riggins RB , Lan JP, Dunderdale J, Zwart A, and Clarke R. ERR



/AP1 signaling drives cholesterol production and Tamoxifen resistance in breast cancer. AACR Annual Meeting, Denver, CO 2009.

Riggins RB , Lan JP, Zwart A, and Clarke R. ERR



/AP1 signaling drives cholesterol production and

Tamoxifen resistance in breast cancer. ENDO Annual Meeting, Washington, DC 2009.

Elhelu L, Kumar D, Hilakivi-Clarke L, and Riggins RB . Bisphenol-A modulates the expression of estrogen related receptor gamma (ERR



) target genes in MCF-10A normal mammary epithelial cells.

HBCU-UP National Research Conference, Washington, DC 2009.

Mazzotta MM, Liu MC, Clarke R, and Riggins RB . ERK/MAPK regulation of ERR



in Tamoxifenresistant breast cancer. AACR Annual Meeting, Washington, DC 2010.

Maniya OZ, Zwart A, Chen L, Xuan J, Clarke R, and Riggins RB . The role of COUP transcription factors in Tamoxifen resistant breast cancer cells. AACR Annual Meeting, Washington, DC 2010.

Rechache NS, Riggins RB , Shajahan AN, Zwart A, and Clarke R. The role of autophagy in taxane resistant breast cancer models. AACR Annual Meeting, Washington, DC 2010.

Riggins CV 25

Ning Y, Riggins RB , Shajahan AN, Zwart A, and Clarke R. Downregulating IRF1 by siRNA promotes resistance to Fulvestrant in sensitive breast cancer cells partially via the Ras/Raf/MEK/ERK pathway. AACR Annual Meeting, Washington, DC 2010.

*Shajahan AN, Riggins RB , Zwart A, Hickman FE, and Clarke R. XBP1 and the unfolded protein response in antiestrogen resistance in breast cancer. AACR Annual Meeting, Washington, DC 2010.

*abstract was selected for oral presentation.

Elhelu L, Kumar D, Hilakivi-Clarke R, and Riggins RB . Bisphenol-A modulates multiple signaling pathways in breast cancer cells. Annual Biomedical Research Conference for Minority Students,

Charlotte, NC 2010

Gusev Y, Gauba R, Bhuvaneshwar K, Riggins RB , Clarke R, and Madhavan S. Bioinformatics pipeline for in silico analysis of breast cancer datasets to answer key systems biology questions.

AACR-NCI Conference on Systems Biology: Confronting the Complexity of Cancer, San Diego, CA

2011.

Hu R, Shajahan AN, Riggins RB , and Clarke R. XBP1 regulates NfkappaB signaling in antiestrogen resistant breast cancer cells. DoD Era of Hope Meeting, Orlando, FL 2011.

Rechache NS, Riggins RB , Shajahan AN, Zwart A, and Clarke R. The role of autophagy in taxane resistant breast cancer models. DoD Era of Hope Meeting, Orlando, FL 2011.

Riggins RB , Rone JD, Bebu I, Clarke R, and Haddad B. Role of Interferon Regulatory Factor-1 (IRF1) in Familial Breast Cancer: Primary Driver or Modifier of Carcinogenesis? DoD Era of Hope Meeting,

Orlando, FL 2011.

Gong T, Xuan J, Chen L, Riggins RB , Li H, Hoffman E, Clarke R, and Wang Y. Motif-guided sparse decomposition of gene expression data for regulatory module identification. Intelligent Systems for

Molecular Biology/European Conference on Computational Biology, Vienna, Austria 2011.

Gong T, Xuan J, Riggins RB , Clarke R, and Wang Y. Bayesian data integration for regulatory module identification. 25 th

Conference on Artificial Intelligence (AAAI-11), San Francisco, CA 2011.

*Liu MC, Dixon JM, Xuan J, Riggins RB , Chen L, Wang C, Cho Y, Zhu Y, Jin L, Zwart A, Wang M,

Klimach U, Wang Y, Renshaw L, Larionov A, Miller WR, and Clarke R. Molecular signaling distinguishes early ER positive breast cancer recurrences despite adjuvant Tamoxifen. CTRC-AACR

San Antonio Breast Cancer Symposium, San Antonio, TX 2011.

*abstract was selected for oral presentation.

Chen X, Xuan J, Riggins RB , Shajahan AN, Clarke R, and Wang Y. Reconstruction of Transcription

Regulatory Networks by Stability-based Network Component Analysis. International Symposium on

Bioinformatics Research and Applications, Dallas, TX 2012.

Heckler M, Albanese C, and Riggins RB . GW4716 selectively targets multiple p53 mutant cancer models. AACR Annual Meeting, Washington, DC 2013.

Riggins CV 26

Riggins RB , Heckler MM, Thakor H, Schafer CC, Singh S, Tian Y, Gusev Y, Madhavan S, and Wang

Y. Phospho-dependent regulation of ERR



expression, transcriptional activity, and Tamoxifen resistance in ER+ breast cancer. AACR Annual Meeting, Washington, DC 2013.

Goerlitz D, Li X, Islam MD, Byers SW, and Riggins RB . Effects of RNA degradation on performance of the Illumina Whole-Genome DASL HT Assay. International Symposium of the Association of

Biomolecular Resource Facilities, Albuquerque, NM 2014.



Weiner LM. Acquisition of estrogen independence induces TOB1-related mechanisms supporting breast cancer cell proliferation. AACR Annual Meeting, Philadelphia, PA 2015.

Riggins CV 27

cv - Georgetown University

Related documents

Products

Support

cv - Georgetown University

Related documents

Add this document to collection(s)

Add this document to saved

Suggest us how to improve StudyLib